CellGenix® rh Flt-3L
GMP and Preclinical grade
CellGenix Recombinant Human Flt-3L reliably supports the proliferation of hematopoietic stem cells (HSCs). CellGenix rh Flt-3L is produced in our dedicated animal-free facility ensuring maximum safety for optimal use in ATMP manufacturing.
FMS-like Tyrosine Kinase 3 Ligand (FLt-3L) is a cytokine that regulates proliferation and differentiation of various blood cell progenitors.
Flt-3L is used in the cell and gene therapy space for the ex vivo expansion of HSCs that are used for transplantation.
CellGenix GMP Recombinant Human Flt-3L is produced following all applicable GMP guidelines and allows for the safe use in accordance with USP Chapter <1043> and Ph. Eur. General Chapter 5.2.12.
Our GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
CellGenix® Recombinant Human FMS-like Tyrosine Kinase 3 Ligand
CellGenix® GMP rh Flt-3L
CellGenix® Preclinical rh Flt-3L
CellGenix® rh Flt-3L
- Produced in our dedicated animal-free facility
- Compliant to USP Chapter <1043> and Ph. Eur. General Chapter 5.2.12 (GMP)
- FDA Drug Master File available (GMP)
GMP & Preclinical Grade
- Seamless transition from preclinical development to ATMP manufacturing
Highest GMP Quality Standard
- High lot-to-lot consistency – save time on revalidations
- Performance reliability – rely on consistent product performance
- Highest purity – ensure the safety of your ATMP
- Extremely low endotoxin levels – improve safety and reproducibility
- Expert regulatory & technical support – rely on experience
Read more about our GMP Quality
Safe │ GMP Compliant │ Reliable
Expressed in E. coli
Truncated human Flt-3L, accession # P49771, Thr27-Ala181
Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5
Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP
|Molecular weight||18.6 kDa||18.6 kDa|
|Purity||≥ 95% as determined by SDS-PAGE||≥ 97% as determined by SDS-PAGE|
|Activity||≥ 0.5 x 106 IU/mg, calibrated against NIBSC #96/532||0.5 – 2.0 x 106 IU/mg, calibrated against NIBSC #96/532|
Batch specific activity on CoA
|Endotoxin level||< 1000 EU/mg||≤ 50 EU/mg|
|Intended use||Intended for preclinical ex vivo use. Not intended for human in vivo application.||Intended for clinical ex vivo use. Not intended for human in vivo application.|
Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials or 500 µg/ml for 1 mg vials.
Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.
≥ 6 months from date of shipping. Please refer to Certificate of Analysis (CoA) for the exact expiry date.
Storage & Stability
Store lyophilized cytokine at -20°C to -80°C.
Store a 250 µg/ml reconstituted cytokine solution:
• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container.
• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.
Avoid repeated freeze/thaw cycles.
CellGenix GMP rh Flt-3L has an activity of 0.5 – 2.0 × 106 IU/mg
The activity of GMP rh Flt-3L was measured in a cell proliferation assay using the Flt-3L-dependent cell line OCI-AML5. It was calibrated against NIBSC #96/532.
You can find the batch specific activity on the Certificate of Analysis (CoA).
We offer the following to assist you with your regulatory approval process:
- Comprehensive documentation (e.g. DMFs, Regulatory Support Files, Certificates of Origin)
- Outstanding QC support (e.g. extensive stability data)
- The possibility to audit our production site
- Detailed batch specific test results on our Certificates of Analysis
- Change notifications prior to relevant changes
Customized solutions can be provided to meet special compliance needs. Contact our Regulatory Support Team for all your regulatory requests & questions:
Phone: +49 761 88 88 9-302
In order to stay up-to-date with the international guidelines for raw materials, we are in constant interaction with regulatory authorities worldwide. In this regard, we amongst others helped defining the European guidelines which are outlined in the new general chapter Ph. Eur. monograph 5.2.12.
- Gene therapy in a patient with Sickle Cell disease
Ribeil, JA. et al., 2017, The New England Journal of Medicine
- A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis
Hou, Y. et al., 2015, Stem Cell Research & Therapy
- Low rate of infusional toxicity after expanded cord blood transplantation
Bear, AS. et al., 2014, Cytotherapy
- 3′, 4′-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.
Kaur, K. et al., 2013, Stem Cell Research & Therapy
- MRI tracking of FePro labeled fresh and cryopreserved long term in vitro expanded human cord blood AC133+ endothelial progenitor cells in rat glioma
Janic, B. et al., 2012, PLoS One
- Is Anticancer Vaccine Possible: Experimental Application of Produced mRNA Transfected Dendritic Cells Derived from Enriched CD34+ Blood Progenitor Cells
Lazarova, P. et al., 2012, Immunodeficiency, Chapter 3
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Spanholtz, J. et al., 2011, PloS One
- Polarization and migration of hematopoietic stem and progenitor cells rely on the RhoA/ROCK I pathway and an active reorganization of the microtubule network
Fonseca, AV. et al., 2010, The journal of biological chemistry
- Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution
Delaney, C. et al., 2010, Nature Medicine